Axel Glasmacher

ORCID: 0000-0003-2611-7656
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Neutropenia and Cancer Infections
  • Antifungal resistance and susceptibility
  • Fungal Infections and Studies
  • Multiple Myeloma Research and Treatments
  • CNS Lymphoma Diagnosis and Treatment
  • Acute Myeloid Leukemia Research
  • Cancer Treatment and Pharmacology
  • Lymphoma Diagnosis and Treatment
  • Protein Degradation and Inhibitors
  • Glioma Diagnosis and Treatment
  • Bacterial Identification and Susceptibility Testing
  • Chronic Lymphocytic Leukemia Research
  • Acute Lymphoblastic Leukemia research
  • Retinoids in leukemia and cellular processes
  • Chronic Myeloid Leukemia Treatments
  • Hematopoietic Stem Cell Transplantation
  • Cancer therapeutics and mechanisms
  • Blood disorders and treatments
  • Infectious Diseases and Mycology
  • Bone health and treatments
  • Hematological disorders and diagnostics
  • Oral health in cancer treatment
  • Sepsis Diagnosis and Treatment
  • Brain Metastases and Treatment
  • Advanced Breast Cancer Therapies

University of Bonn
2006-2025

University Hospital Bonn
2005-2023

Bristol-Myers Squibb (Switzerland)
2006-2016

University of Cologne
2003-2010

Heidelberg University
2003-2010

TU Dresden
2010

Institute of Neurobiology
2010

University Hospital Ulm
2010

Düsseldorf University Hospital
2010

Krankenhaus der Barmherzigen Brüder Trier
2010

To evaluate response rate, duration, overall survival (OS), and toxicity in primary CNS lymphoma (PCNSL) after systemic intraventricular chemotherapy with deferred radiotherapy.From September 1995 to July 2001, 65 consecutive patients PCNSL (median age, 62 years) were enrolled onto a pilot phase II study evaluating without radiotherapy. A high-dose methotrexate (MTX; cycles 1, 2, 4, 5) cytarabine (ARA-C; 3 6)-based therapy (including dexamethasone, vinca-alkaloids, ifosfamide,...

10.1200/jco.2003.04.056 article EN Journal of Clinical Oncology 2003-11-04

Summary Antifungal prophylaxis for allogeneic haematopoietic stem‐cell transplant (alloHCT) recipients should prevent invasive mould and yeast infections (IFIs) be well tolerated. This prospective, randomized, open‐label, multicentre study compared the efficacy safety of voriconazole (234 patients) versus itraconazole (255 in alloHCT recipients. The primary composite endpoint, success prophylaxis, incorporated ability to tolerate drug ≥100 d (with ≤14 interruption) with survival day 180...

10.1111/j.1365-2141.2011.08838.x article EN other-oa British Journal of Haematology 2011-08-22

Purpose To assess the impact of allogeneic hematopoietic stem-cell transplantation (HSCT) from matched related donors (MRDs) and unrelated (MUDs) on outcome in high-risk patients with acute myeloid leukemia (AML) within a prospective multicenter treatment trial. Patients Methods Between 1998 2004, 844 (median age, 48 years; range, 16 to 62 years) AML were enrolled onto protocol AMLHD98A that included risk-adapted strategy. High risk was defined by presence unfavorable cytogenetics and/or no...

10.1200/jco.2010.28.6856 article EN Journal of Clinical Oncology 2010-08-31

Caspofungin inhibits synthesis of beta-1,3-glucan, an essential component the Aspergillus cell wall. This echinocandin has demonstrated efficacy (45% success) as salvage monotherapy invasive aspergillosis (IA). Interest remains to whether caspofungin, in combination with other antifungal classes, can improve against IA.The study involved 53 adults documented IA who were refractory or intolerant standard therapy and received caspofungin 1 mold-active agent (at investigator's discretion)....

10.1002/cncr.22348 article EN Cancer 2006-11-17

ABSTRACT Infection is the main treatment-related cause of mortality in cancer patients. Rapid and accurate diagnosis to facilitate specific therapy febrile neutropenia therefore urgently warranted. Here, we evaluated a commercial PCR-based kit detect DNA 20 different pathogens (SeptiFast) setting after chemotherapy. Seven hundred eighty-four serum samples 119 neutropenic episodes (FNEs) 70 patients with hematological malignancies were analyzed compared clinical, microbiological, biochemical...

10.1128/jcm.00491-09 article EN Journal of Clinical Microbiology 2009-07-02

Serum carbohydrate antigen 19-9 (CA 19-9) has been identified as a useful tumour marker for diagnosis of exocrine pancreatic carcinoma, but its value evaluating the response to chemotherapy with gemcitabine is not clear. Tumour regression in carcinoma hard determine due massive desmoplastic tissue. Furthermore, objective does automatically transcribe into better survival. Therefore, clinical benefit response, composed parameter consisting factors like performance status, pain, and body...

10.1038/sj.bjc.6601263 article EN cc-by-nc-sa British Journal of Cancer 2003-10-01

Clostridium difficile is the most important cause of nosocomial infectious diarrhea. The importance C. difficile—associated diarrhea (CDAD) has been poorly investigated in patients with neutropenia who have hematologic malignancies. A retrospective chart review all treated leukemia ward a university medical center during 1991–2000 determined that 875 courses myelosuppressive chemotherapy were administered. CDAD occurred 7.0% cycles. In 8.2% patients, severe enterocolitis developed. Two died...

10.1086/322616 article EN Clinical Infectious Diseases 2001-09-15

This study analyses invasive fungal infections in neutropenic patients with haematological malignancies during antifungal prophylaxis itraconazole. From September 1994 to December 1998 20 developed infections. Two suffered from disseminated by yeasts and 18 pulmonary moulds (eight proven, 10 highly probable high-resolution CT scans). In these the itraconazole trough concentrations exceeded 500 ng ml-1 (measured high performance liquid chromatography) significantly less often (median 48%,...

10.1046/j.1439-0507.1999.00505.x article EN Mycoses 1999-09-01

To evaluate long-term progression-free survival and overall survival, quality of life, cognitive function in primary central nervous system lymphoma after systemic intraventricular chemotherapy without radiotherapy.A follow-up was conducted on surviving patients having been enrolled a pilot/phase II trial between September 1995 December 2001. Initially, 65 (median age, 62 years) had treated with radiotherapy. All living were contacted, neurological examination, comprehensive...

10.1002/ana.21824 article EN Annals of Neurology 2009-08-11

ObjectivesInvasive fungal infections (IFIs) contribute significantly to mortality and morbidity in patients receiving myelosuppressive chemotherapy for haematological malignancies. The present study investigates the overall survival (OS), infection-related changes treatment of IFIs our department from 1995 until 2006.

10.1093/jac/dkp507 article EN cc-by-nc Journal of Antimicrobial Chemotherapy 2010-01-27

<b>Background: </b> Combined radio- and chemotherapy for primary CNS lymphoma (PCNSL) is associated with a considerable risk of long-term neurotoxicity. The impact high-dose methotrexate (MTX)-based alone on cognition quality life (QOL) controversial. <b>Objective: To assess the tumor itself its treatment MTX-based QOL in patients PCNSL. <b>Methods: Prospective neuropsychological examinations MRI were performed PCNSL who complete remission more than 12 months after completion chemotherapy. A...

10.1212/01.wnl.0000156350.49336.e2 article EN Neurology 2005-04-12

This trial studied the efficacy and safety of itraconazole fluconazole in prevention invasive fungal infections neutropenic patients with haematological malignancies.An 8 week, open-label, randomized, parallel-group, multicentre comparing oral solution (2.5 mg/kg twice daily; N=248) or capsules (400 mg N=246) 494 anticipated profound neutropenia (i.e. neutrophil count expected to be <500 cells/mm3 for at least 10 days) from tertiary care centres.Invasive were reported 4 out 248 (1.6%) group...

10.1093/jac/dki440 article EN Journal of Antimicrobial Chemotherapy 2005-12-08

We have previously shown that a trough concentration of at least 500 ng ml −1 itraconazole is necessary for an effective antifungal prophylaxis in neutropenic patients. Since the bioavailability reduced these patients, satisfactory dosing regimen remains to be defined. In this study, six regimens with capsules 400, 600 or 800 mg day , solution 400 (additional loading dose: 2 days), 7 days, s/c1200) were compared during 160 courses myelosuppressive chemotherapy 123 patients acute leukaemia....

10.1046/j.1439-0507.1999.00518.x article EN Mycoses 1999-12-01
Coming Soon ...